English
This article is from Journal of Pharmacology & Pharmacotherapeutics , volume 4 . Abstract Introduction:: The epidermal growth factor receptor inhibitors (EGFRIs), cetuximab and panitumumab, represent an effective treatment option for patients affected by metastatic colorectal cancer (mCRC); furthermore, they are relatively devoid of systemic toxicities, which are commonly observed with standard cytotoxic chemotherapy. However, the majority of patients treated with these monoclonal antibodies (mAbs), will experience dermatologic toxicities, most notably the papulopustular skin rash, which can impact quality-of-life and affect adherence to therapy. This paper reviews the most recent practices in the management of skin rash related to anti-epidermal growth factor receptor (EGFR) mAbs, cetuximab and panitumumab, in the treatment of mCRC. Materials and Methods:: We reviewed relevant literature regarding dermatologic toxicities associated with anti-EGFR mAbs in order to give important indications about prevention and reactive treatment of skin rash. Results:: Two case reports were presented to show how skin rash could hamper mAb EGFRIs use in clinical practice, underscoring the need of i
Sign in with your free account to read, download EPUBs or listen.
Ebook · Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review. · Leporini, Christian, Saullo, Francesca, Filippelli, Gianfranco, Sorrentino, Antonio, Lucia, Maria, Perri, Gino, Gattuta, Gaetana La, Infusino, Stefania · Internet Archive